Ушбу ишга иқтибос қилган ишлар

5 та иш

Иш: Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies

1. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

   Manh-Cuong Vo, Van-Dinh-Huan Tran, Van‐Tan Nguyen +5

   МақолаCAR-T cell therapy researchJournal of Hematology & Oncology20250 иқтибос

   ABIABI:AkademIndex/openalex/2025.article.000083

2. Next-generation CAR-T and CAR-NK cell therapies in hematologic malignancies: engineering for persistence, specificity, and safety

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   МақолаCAR-T cell therapy researchDiscover Oncology20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.005310

3. Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy

   Mutaz Jamal Al-khreisat, Waleed K. Abdulsahib, Ihsan Khudhair Jasim +6

   МақолаCancer Immunotherapy and BiomarkersAnnals of Hematology20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.009488

4. Advances in monitoring and therapy from minimal residual disease to CAR-T cells in multiple myeloma and precursor disorders

   Amr Ali Mohamed Abdelgawwad El‐Sehrawy, Ghaleb Oriquat, Sokhib Saidov +5

   МақолаCAR-T cell therapy researchClinica Chimica Acta20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.017391

5. CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy

   E. A Nemilostiva, O. A Paevskaya, Shuxrat Boymuradov +2

   МақолаPluripotent Stem Cells ResearchClinical & Translational Oncology20260 иқтибос

   ABIABI:AkademIndex/openalex/2026.article.018185